Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia  by van der Laan, Hans Paul et al.
Radiotherapy and Oncology 115 (2015) 56–62Contents lists available at ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comPrediction of dysphagiaAcute symptoms during the course of head and neck radiotherapy
or chemoradiation are strong predictors of late dysphagiaqhttp://dx.doi.org/10.1016/j.radonc.2015.01.019
0167-8140/ 2015 Elsevier Ireland Ltd. All rights reserved.
q Meeting presentation: Oral presentation at ESTRO33, Vienna, Austria, 4-8 April,
2014.
⇑ Corresponding author at: Department of Radiation Oncology, University
Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
E-mail address: h.p.van.der.laan@umcg.nl (H.P. van der Laan).Hans Paul van der Laan a,⇑, Hendrik P. Bijl a, Roel J.H.M. Steenbakkers a, Arjen van der Schaaf a,
Olga Chouvalova a, Johanna G.M. Vemer-van den Hoek a, Agata Gawryszuk a, Bernard F.A.M. van der Laan b,
Sjoukje F. Oosting c, Jan L.N. Roodenburg d, Kim Wopken a, Johannes A. Langendijk a
aDepartment of Radiation Oncology; bDepartment of Otorhinolaryngology/Head and Neck Surgery; cDepartment of Medical Oncology; and dDepartment of Oral and Maxillofacial
Surgery, University of Groningen, University Medical Center Groningen, The Netherlands
a r t i c l e i n f oArticle history:
Received 13 October 2014
Received in revised form 17 December 2014
Accepted 16 January 2015
Available online 16 March 2015
Keywords:
Head and neck cancer
IMRT
Swallowing dysfunction
Acute symptoms
Prediction modelsa b s t r a c t
Purpose: To determine if acute symptoms during deﬁnitive radiotherapy (RT) or chemoradiation (CHRT)
are prognostic factors for late dysphagia in head and neck cancer (HNC).
Material and methods: This prospective cohort study consisted of 260 HNC patients who received deﬁni-
tive RT or CHRT. The primary endpoint was grade 2–4 swallowing dysfunction at 6 months after complet-
ing RT (SWALM6). During treatment, acute symptoms, including oral mucositis, xerostomia and
dysphagia, were scored, and the scores were accumulated weekly and entered into an existing reference
model for SWALM6 that consisted of dose–volume variables only.
Results: Both acute xerostomia and dysphagia were strong prognostic factors for SWALM6. When acute
scores were added as variables to the reference model, model performance increased as the course of
treatment progressed: the AUC rose from 0.78 at the baseline to 0.85 in week 6. New models built for
weeks 3–6 were signiﬁcantly better able to identify patients with and without late dysphagia.
Conclusion: Acute xerostomia and dysphagia during the course of RT are strong prognostic factors for late
dysphagia. Including accumulated acute symptom scores on a weekly basis in prediction models for late
dysphagia signiﬁcantly improves the identiﬁcation of high-risk and low-risk patients at an early stage
during treatment and might facilitate individualized treatment adaptation.
 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 115 (2015) 56–62Dysphagia is one of the most important side effects after deﬁni-
tive radiotherapy (RT) for head and neck cancer (HNC), also if RT is
combined with chemotherapy (CHRT) [1–3]. Approximately one-
third of the HNC patients treated with RT or CHRT sustain moder-
ate to severe symptoms that may persist months to years after
treatment. These symptoms impair normal swallowing, leading
to weight loss and requiring dietary changes. The severity ranges
from minor swallowing problems with a normal diet to complete
dependence on tube feeding. Previous studies showed that dyspha-
gia has a detrimental impact on quality of life after treatment of
HNC [1,4].
Recently, Christianen et al. developed a multivariable Normal
Tissue Complication Probability (NTCP) model for grade 2–4 swal-
lowing dysfunction 6 months after completion of treatment(SWALM6), showing that the development of late dysphagia
mainly depended on the radiation dose to the swallowing organs
at risk (SWOARs), including the superior pharyngeal constrictor
muscle (superior PCM) and the supraglottic larynx [5,6]. This
multivariable NTCP model enables identiﬁcation of patients at risk
for late dysphagia and the development of new radiation delivery
techniques, such as swallowing sparing intensity modulated RT
(SW-IMRT) [7,8].
Although this multivariable NTCP model for late dysphagia per-
formed well in terms of discrimination (AUC = 0.80) [6], the
explained variance, indicating the relevance of the variables in
the model in relation to the endpoint, remained relatively low.
The variable toxicity proﬁles of patients may be explained by
individual differences in sensitivity to develop radiation induced
side-effects. Furthermore, late toxicity may develop partially as a
consequence of early symptoms. Therefore, we hypothesized that
patients with early-onset, more severe or longer lasting acute
symptoms are at a higher risk of developing late dysphagia.
The ﬁrst objective of our study was to test the hypothesis that
acute symptoms during the course of treatment are signiﬁcantly
Table 1
Patient and treatment characteristics and frequencies.
Number of patients %
Gender
Male 197 76
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tive was to determine if and to what extent model performance
would improve as a result of including acute symptoms as prog-
nostic factors in the reference multivariable NTCP model for
SWALM6.Female 63 24
Age (years)
Mean age (years) 62.4
18–65 159 61
>65 101 39
Tumor classiﬁcation
Tx 1 0
T1 52 20
T2 115 44
T3 54 21
T4 38 15
Node classiﬁcation
N0 140 54
N1 27 10
N2 3 1
N2a 6 2
N2b 38 15
N2c 39 15
N3 7 3
Neck irradiation
Local or unilateral 86 33
Bilateral 174 67
Primary site
Larynx 138 53
Hypopharynx 24 9
Oral cavity 6 2
Oropharynx 68 26
Nasopharynx 18 7
Other 6 2
Treatment modality
5 fractions per week 48 18
6 fractions per week 137 53
Concomitant chemotherapy 65 25
Radiotherapy + cetuximab 10 4
Radiation technique
3D-CRT 62 24
Parotid sparing IMRT 108 42
Swallowing sparing IMRT 90 35
Patients
Overlapping with previous study [6] 110 42
Total number of patients 260 100Materials and methods
Patients
We acquired the patient data for our study from the HNC data-
base at our department. All patients with HNC referred for RT or
CHRT are subjected to a prospective data collection program in
which baseline, acute (weekly during RT) and late (six months after
RT) radiation-induced side effects are assessed on a routine basis.
For the current study, we included patients who received deﬁnitive
RT, CHRT or RT with cetuximab for Stage I–IV (M0) squamous cell
HNC. We excluded patients who had previously undergone surgery
and/or RT in the head and neck region, who had prior malignancies
and those with distant metastases or locoregional recurrences at
6 months after treatment. Patients with grade 1–4 dysphagia at
the baseline and patients with missing data on acute symptoms
in two or more subsequent weeks were also excluded. In 413 cases
treated with deﬁnitive radiotherapy, chemoradiation or radiother-
apy plus cetuximab, the dosimetric data and the SWALM6 scores
were both available. Patients were excluded as a consequence of:
(1) the exclusion criteria (n = 82); (2) missing baseline toxicity data
(n = 1); or (3) missing acute symptom data (n = 3), respectively.
Eventually, of the remaining 327 patients, 67 were excluded
because of a baseline dysphagia grading of more than zero. The
ﬁnal study population consisted of 260 patients in whom all pre-
treatment, treatment and toxicity data were prospectively
assessed. Table 1 shows the demographic, tumor and treatment
characteristics of the study population.
All patient data was obtained as part of a prospective data
registration programwithin the framework of routine clinical prac-
tice. The Dutch Medical Research Involving Human Subjects Act is
not applicable to data collection as part of routine clinical practice.
Therefore the hospital ethics committee exempted this study from
the ethical approval requirement.Endpoint and acute symptoms
The primary endpoint was physician-rated dysphagia grade 2–4
at 6 months after the completion of RT (SWALM6) according to the
Late European Organisation for Research and Treatment of Cancer/
Radiation Therapy Oncology Group (EORTC/RTOG) Radiation
Morbidity Scoring Criteria [9]. Patients with this endpoint were
unable to eat solid food and could only eat semisolid (pureed) food
(grade 2) or worse. Acute and late radiation-induced side effects
were assessed at the baseline and weekly during the course of
treatment. The acute symptom scores for oral mucositis, xerosto-
mia and dysphagia are listed in Table 2. If acute symptom scores
were missing for only one week for a particular patient, the scores
from the previous week were used.Treatment
Patients were treated with three-dimensional conformal radio-
therapy (3D-CRT) or intensity modulated radiotherapy (IMRT),
with or without concomitant chemotherapy or cetuximab. These
treatment regimes have been described previously in more detail
[6]. The various organs at risk were delineated on the planning
CT according to previously published delineation guidelines
[10,11]. All original 3D-CRT and IMRT treatment plans, with the
corresponding dose–volume parameters of the organs at risk, wereevaluated in a research version of the Pinnacle3 treatment-plan-
ning system (version 9.1, Philips Radiation Oncology Systems,
Fitchburg, WI, USA).Reference model
First, we evaluated the reference multivariable NTCP model in
our cohort (Table 1) by calculating the model value (linear predic-
tor) for each patient with the model intercept and regression
coefﬁcients as published by Christianen et al. These values were
6.09 + (0.057 mean dose (Gy) in the superior
PCM) + (0.037 mean dose (Gy) in the supraglottic larynx), and
the subsequent NTCP value for each individual patient. In addition,
we evaluated the performance of this model in the current study
population relative to that in Christianen et al. [6] in terms of
explained variance, calibration and discrimination. The linear pre-
dictor of the reference model was entered as the reference (base-
line) model variable in all subsequent models.Standardized acute symptoms z-scores
The acute symptom scores were assessed weekly (Table 2). Each
acute symptom score was subsequently transformed into a weekly
standardized accumulated z-score for two reasons: (1) an accumu-
lated score, calculated by adding the scores of previousweeks, com-
bined the severity and duration of the acute symptom in one value;
Table 2
Physician rated toxicity, frequencies.
Late EORTC/RTOG dysphagia (6 months after RT) n %
EORTC/RTOG grade 0–1 197 76
EORTC/RTOG grade 2–4 63 24
Crude acute toxicity scores Week 3 Week 4 Week 5 Week 6
n % n % n % n %
Oral mucositis
0 None 99 38 63 25 45 18 41 16
1 Erythema of mucosal membrane 94 36 81 31 71 27 49 19
2 Patchy reaction <1.5 cm 53 21 89 34 86 33 89 34
3 Conﬂuent reaction >1.5 cm 14 5 27 10 58 22 81 31
4 Necrosis or deep ulceration 0 0 0 0 0 0 0 0
Mean accumulated group score (SD) 1.14 (1.16) 2.45 (1.89) 4.05 (2.70) 5.86 (3.57)
Xerostomia
0 None 83 32 55 21 47 18 41 16
1 Symptoms without dietary changes 137 53 113 44 91 35 81 31
2 Symptoms with signiﬁcant dietary changes 38 14 89 34 113 43 132 51
3 Tube feeding, otherwise no adequate intake 2 1 3 1 9 4 6 2
Mean accumulated group score (SD) 1.45 (1.33) 2.60 (1.89) 3.92 (2.48) 5.32 (3.10)
Swallowing dysfunction
0 Normal diet 155 60 90 35 71 27 57 22
1 Soft / Pureed food 73 28 88 34 80 31 78 30
2 Liquid diet 16 6 40 15 42 16 45 17
3 Tube feeding with oral intake possible 15 6 37 14 57 22 67 26
4 Tube feeding without oral intake possible 1 0 5 2 10 4 13 5
Mean accumulated group score (SD) 0.82 (1.31) 1.97 (2.16) 3.42 (3.10) 5.03 (4.10)
Abbreviations: EORTC/RTOG = European Organisation for Research and Treatment of Cancer/Radiation Therapy Oncology Group criteria for adverse effects [9].
58 Acute symptoms predict late dysphagia(2) standardizing the accumulated scores (i.e., expressing each
accumulated score as a number of standard deviations from the
average population score) improved the interpretation of a score.Formulas
For each of the acute symptoms and individual patient (k), an
accumulated symptom score (Ck;w) in a particular week of radio-
therapy (w) was calculated by adding up the scores (Sk;j) of all sub-
sequent weeks (j) from week 1 to week w.
Ck;w ¼
Xw
j¼1
Sk;j
For each week of radiotherapy (w), the mean accumulated acute
symptom score ðlwÞ and standard deviation ðrwÞ were calculated
for the whole population of n patients.
lw ¼
1
n
Xn
k¼1
Ck;w
rw ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPn
k¼1ðCk;w  lwÞ2
n 1
s
Finally, a standardized z-score ðZk;wÞ for the accumulated symp-
tom scores of patient k in week w was deﬁned as
Zk;w ¼ ðCk;w  lwÞ=rwWeekly dynamic models
The acute symptom proﬁle of individual patients became
clearer as RT progressed. Because new acute symptom information
was added each week, these weekly models were referred to as
dynamic models.
The z-scores were available for each patient, each week of RT
and each acute symptom type (oral mucositis, xerostomia anddysphagia). The next step was to build subsequent dynamic mod-
els for each week (weeks 1, 2, 3, 4, 5, and 6). The variables in a
dynamic model consisted of the aforementioned linear predictor
of the reference model and the z-scores for the acute symptoms.
Then, a stepwise backward (Wald) logistic regression procedure
was used to exclude acute symptom variables from the model with
p-removal >0.157.Internal validation and model performance
All dynamic models were subjected to internal validation
with a bootstrapping procedure (2000 bootstraps for each analy-
sis) in order to correct (shrink) the models (slope and intercept)
for optimism [12]. This was done to obtain realistic regression
coefﬁcients for the model variables that are representative for
populations similar to the development sample. For each
dynamic model, the area under the receiver operating character-
istic curve (ROC-curve AUC), the explained variance and calibra-
tion were determined. In addition, model improvement measures
were determined, i.e., the Net Reclassiﬁcation Improvement
(NRI) and the Integrated Discrimination Improvement (IDI) rela-
tive to the reference model were determined for each dynamic
model. The NRI quantiﬁed the difference in the sum of the
sensitivity and speciﬁcity between two models (using a >50%
NTCP criterion to classify patients as high-risk patients). The
IDI quantiﬁed the difference in the discrimination slopes of
two models. Dynamic models were only accepted for a particular
week when these yielded a signiﬁcantly better (p < 0.05) classiﬁ-
cation and discrimination (NRI and IDI) of patients with and
without late dysphagia on the basis of the model predictions
compared with the existing reference model.NTCP calculation
The probability that a patient developed the complication
(NTCP), i.e., late dysphagia, was calculated with a logistic regres-
sion model
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with the linear predictor (S) deﬁned as
S ¼ b0 þ
X
i
bi  xi
where b0 and bi were the model parameters and xi the predictor
variables.
Results
Reference model
Of the 260 patients included in the ﬁnal analyses (Table 1), 63
(24.2%) developed SWALM6 (Table 2). The linear predictor variable
obtained from the reference model of Christianen et al. (compris-
ing the intercept, the mean dose in the superior PCM and the mean
dose in the supraglottic larynx with corresponding regression
coefﬁcients) was a signiﬁcant factor in all subsequent models in
the current study (Table 3). The reference model yielded an AUC
value of 0.78 in our cohort (Table 4). This value was comparable
(0.80) to the AUC obtained by Christianen et al. [6].Discarded models and predictors
In univariable analysis, all acute symptom z-scores in weeks 2
through 6 (and acute xerostomia in weeks 1 through 6) were sig-
niﬁcantly associated with SWALM6 (p < 0.001). In the multivari-
able models, however, oral mucositis was not selected as an
independent prognostic factor at any time point (p > 0.157). In
the multivariable models, acute xerostomia in weeks 1 and 2 was
a signiﬁcant factor for SWALM6. Although the performance of theTable 3
Final models.
Variables b
Uncorrected Corr
Reference model in current cohort
Linear predictor reference model [6] 0.881 0.89
Intercept 0.113 0.1
Model week 3
Linear predictor reference model 0.739 0.69
Xerostomia z-value 0.427 0.40
Dysphagia z-value 0.483 0.45
Intercept 0.419 0.4
Model week 4
Linear predictor reference model 0.655 0.62
Xerostomia z-value 0.368 0.35
Dysphagia z-value 0.741 0.70
Intercept 0.614 0.6
Model week 5
Linear predictor reference model 0.612 0.58
Xerostomia z-value 0.458 0.43
Dysphagia z-value 0.725 0.69
Intercept 0.736 0.7
Model week 6
Linear predictor reference model 0.556 0.53
Xerostomia z-value 0.559 0.53
Dysphagia z-value 0.768 0.73
Intercept 0.885 0.8
Binary endpoint: physician-rated dysphagia grade 2–4 at 6 months after the completio
Criteria [9].
Abbreviations: b = Logistic regression coefﬁcient; EORTC/RTOG = European Organisation fo
Ratio; z-value = Standardized mean difference of the accumulated toxicity score ((accum
accumulated score).
* In addition to the uncorrected model parameters the corrected b values after internweek 1 and 2 models improved compared to the reference model
in our cohort (ROC-curve AUC: 0.792 and 0.804, R2: 0.276 and
0.300, respectively), these models did not result in a signiﬁcant
NRI, nor a signiﬁcant IDI compared to the reference model.Dynamic models
Acute xerostomia and acute dysphagia in weeks 3, 4, 5 and 6
were signiﬁcant prognostic factors for SWALM6 (Table 3). The
dynamic NTCP models in these weeks all performed better than
the reference NTCP model in our cohort. Classiﬁcation of high-risk
patients was signiﬁcantly better with the dynamic models
(Table 4). For example, the NRI ranged from 0.212 in week 3 to
0.303 in week 6 (p < 0.001). The discrimination slope of the refer-
ence model was 0.165, while in the dynamic models it ranged from
0.247 in week 3, to 0.301 in week 6. This corresponds with a sta-
tistically signiﬁcant IDI (p < 0.001).
The duration and severity of acute xerostomia and acute dys-
phagia strongly affected the NTCP values of SWALM6 (Fig. 1). For
example, in the quartile of patients who had the worst acute symp-
toms in week 4, SWALM6 was observed in 54% of the cases. The
week 4 model predicted an average NTCP of 54% in this group,
compared to 34% on average with the reference model. In the quar-
tile of patients who had the mildest acute symptoms in week 4,
SWALM6 was observed in 3% of the cases. The week 4 model pre-
dicted an average NTCP of 5% in this group, and the reference
model 13% on average.
We veriﬁed if other variables, listed in Table 1, improved the
ﬁnal dynamic models as presented in this paper, which however
was not the case. This ﬁnding corresponds with the previous ﬁnd-
ings during the development of the reference model.OR
ected* OR 95% CI p-value
1 2.412 1.734–3.355 <0.001
05
2 2.094 1.483–2.955 <0.001
0 1.533 1.047–2.243 0.028
2 1.620 1.148–2.288 0.006
44
6 1.926 1.354–2.739 <0.001
1 1.445 0.945–2.209 0.089
8 2.099 1.426–3.089 <0.001
22 0.541
7 1.844 1.293–2.629 <0.001
9 1.581 1.004–2.491 0.048
6 2.066 1.383–3.086 <0.001
37
1 1.743 1.213–2.505 0.003
4 1.749 1.077–2.840 0.024
4 2.155 1.410–3.295 <0.001
78
n of radiotherapy according to the Late EORTC/RTOG Radiation Morbidity Scoring
r Research and Treatment of Cancer / Radiation Therapy Oncology Group. OR = Odds
ulated patient score — group mean accumulated score)/group standard deviation
al validation and model shrinkage are shown.
Table 4
Model performance measures.
Performance measure Reference model Week 3 model Week 4 model Week 5 model Week 6 model
Overall 2 log likelihood 239.1 219.6 209.6 209.4 206.3
Nagelkerke adjusted R2 0.256 0.345 0.388 0.389 0.402
Discrimination ROC-curve AUC (95%
CI)
0.781 (0.721–0.840) 0.823 (0.768–0.878) 0.847 (0.796–0.898) 0.846 (0.794–0.897) 0.849 (0.797–0.901)
Discrimination slope 0.165 0.247 0.288 0.289 0.301
Calibration Hosmer–Lemeshow
test
X2 = 10.225
(p = 0.250)
X2 = 4.839
(p = 0.775)
X2 = 7.316
(p = 0.503)
X2 = 2.820
(p = 0.945)
X2 = 5.2771
(p = 0.728)
Model
improvement
IDI – 0.082 (p < 0.001) 0.122 (p < 0.001) 0.124 (p < 0.001) 0.135 (p < 0.001)
NRI index – 0.212 (p = 0.006) 0.250 (p = 0.002) 0.281 (p < 0.001) 0.303 (p < 0.001)
Abbreviations: IDI = Integrated Discrimination Improvement (discrimination slope dynamic model — discrimination slope baseline model); NRI = Net Reclassiﬁcation
Improvement (compared to the baseline model and classifying patients with a predicted risk >50% as high risk patients); ROC-curve AUC = area under the receiver operating
characteristics curve.
Fig. 1. Reclassiﬁcation plots. For each patient, the normal tissue complication probability (NTCP) of late dysphagia according to the reference model is plotted against the
NTCP according to the dynamic models of weeks 3, 4, 5 and 6. Patients are grouped (and colored) on the basis of the acute symptom scores in the corresponding weeks: the
quartile of patients (25%) with the lowest acute symptom scores (green) and the quartile with the highest acute symptom scores (red). The remaining patients (50%) had
intermediate acute symptom scores (blue). The diamonds represent the average NTCP values of the patient subgroups.
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The main objective of the current study was to test the hypothe-
sis that acute symptoms during the course of treatment are signiﬁ-
cantly associated to the development of late dysphagia. This
hypothesis was supported by our data. Acute dysphagia and acute
xerostomia in weeks 3–6 of radiotherapy were independent prog-
nostic factors for late RTOG grade 2–4 dysphagia. The second objec-
tive concerned the performance of the reference multivariable
NTCP model for SWALM6. This performance improved signiﬁcantly
when theweekly accumulated scores for acute dysphagia and acute
xerostomia were added as variables: the dynamic models were sig-
niﬁcantly better at distinguishing patients who developed late dys-
phagia from those who did not.These dynamic models could be invaluable in the context of a
more personalized treatment approach. Current dose schedules
are often based on the average toxicity observed in the total
patient population, while our data indicate that, even with the
same dose in the SWOARs, some patients sustain more acute dys-
phagia than average. We demonstrated that these patients also
have a higher risk of late dysphagia, and might therefore be consid-
ered as candidates for a mid-course re-evaluation of their treat-
ment regimes (dose prescriptions and/or radiotherapy
techniques). Several potential means are available to do so. For
example, in week 4, when patients develop more than average
acute symptoms, the dose in the swallowing structures could be
lowered for the remaining fractions, e.g., by decreasing the total
dose in the elective target volumes [13], by using adaptive
H.P. van der Laan et al. / Radiotherapy and Oncology 115 (2015) 56–62 61replanning or by changing to other treatment modalities such as
proton therapy (where available) [14]. Conversely, patients who
remain free from acute symptoms during the entire course of treat-
ment might be candidates for dose escalation strategies. As the
safety and efﬁcacy of such treatment adjustments are not yet clear,
these kind of tailored treatment adjustments based on acute symp-
tom proﬁles may be worthwhile to investigate in future clinical
studies.
The rationale behind the main hypothesis of this study was that
patients differ in their sensitivity to radiation treatment [15,16],
and that patients who are more susceptible to radiation-induced
effects are more prone to develop both acute symptoms and late
toxicity. Acute symptoms can therefore be regarded as biomarkers
for late toxicities and can be used to select patients for adjustment
of their treatment parameters, as described above.
Another possible explanation for the ﬁndings in our study is
consequential late toxicity [17–20]. This is based on the assump-
tion that the radiation dose causes both acute and late toxicity,
while the acute toxicity by itself sets in motion a series of effects
that ultimately lead to late toxicity. This implies that acute toxici-
ties are at least partly in the causal pathway from radiation dose to
late toxicity. Such causality cannot be proven from observational
data, and should therefore be studied and established in a biologi-
cal experimental setting. However, the regression coefﬁcient of the
reference model variable became considerably smaller when the
acute symptom variables were added to the model. This reduction
ranged from 16% in week 3–37% in week 6. This agrees with the
possibility that the observed late dysphagia is partially a
consequential effect, i.e., caused by acute dysphagia [21,22].
Moreover, it is not entirely clear that the same genetic alterations
responsible for radiation sensitivity result in increased acute and
late toxicity. It may very well be that some alterations result in
sensitivity to acute effects and some to late effects. Our data seem
to support that these may be linked. The subset of patients with
severe acute toxicity could be the subject of future research with
the aim to ﬁnd out what the biologic cause of their inherit sensitiv-
ity is. Another explanation for the variation in observed acute
symptoms and late dysphagia might be that the actual delivered
dose distribution was not always similar to the planned dose dis-
tribution, e.g., changes in patient anatomy may occur during the
course of treatment. We are currently investigating such issues
as part of an ongoing effort to improve our models.
The linear predictor of the reference model [6], including base-
line dose–volume parameters, was used as a variable in all our
models. We decided to take this approach instead of ﬁtting a
new baseline model to our data to ensure that the outcomes of this
study added to the reference model for SWALM6. We veriﬁed that
this choice did not have an important effect on the results and con-
clusions of the current study. All models would have ﬁtted slightly
better and would have yielded slightly better performance mea-
sures, while the differences between the models would remain
similar.
Other authors have shown that baseline dysphagia is also a
strong prognostic factor for late dysphagia [5,23]. In most cases,
dysphagia before the start of RT is caused by other factors, such
as local tumor extension or surgery. As we intended to focus on
radiation-induced dysphagia, patients with grade 1–4 dysphagia
at the baseline were excluded from the analysis. This also accounts
for the relatively low incidence (24.2%) of late dysphagia in the cur-
rent study. Therefore, it should be noted that the models presented
in the current study only apply to patients who receive deﬁnitive
RT for squamous cell head and neck cancer and did not have grade
1–4 dysphagia at the baseline.
In the current study, we used cumulative z-scores as candidate
variables for the dynamic prediction models. In patients with other
anatomical tumor sites it has been shown that accumulated acutesymptom scores are more predictive of late symptoms than peak
acute score changes [24]. A cumulative score also offers the ability
to express the onset, severity and persistency of the acute symp-
toms in a single value. The disadvantage of such a value is that it
may be hard to interpret and may be different for different toxici-
ties and different scoring systems. To account for that, the acute
symptoms scores were accumulated each week and then trans-
formed into standardized z-scores [25], and subsequently entered
as variables in the weekly models.Conclusion
Accumulated acute symptoms during the course of RT appear to
be strong predictors of late dysphagia. With the proposed dynamic
models, the NTCP of late dysphagia can be estimated and adjusted
on a weekly basis during the course of treatment. For individual
patients, this may reveal that they are more prone to late dyspha-
gia than expected on the basis of a reference (baseline factors)
model. Or conversely, when they develop no acute symptoms at
all, they may be less prone to late dysphagia. The dynamic models
provide valuable insight into individual therapeutic windows. This
new information may potentially be used to adjust the treatment
strategy mid-course on the basis of the expected risk of late dys-
phagia, enabling a more personalized treatment approach.Conﬂict of interest statement
The authors state that the research presented in this manuscript
is free of conﬂicts of interest.
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